Indonesian registry on atrial fibrillation (OneAF)

Abstract

Background: Data on the optimal therapeutic international normalized ratio (INR) for non-valvular and valvular atrial fibrillation (AF) in Indonesia is currently unavailable. Therefore, we designed the Indonesian Registry on Atrial Fibrillation (OneAF) registry in order to seek a safe and beneficial range of INR in Indonesian patients with non-valvular and valvular AF. Methods/design: The OneAF registry is a nationwide collaboration of the Indonesian Heart Rhythm Society (InaHRS) enrolling all hospitals with cardiac electrophysiologists in Indonesia. It is a prospective, multicentre, nationwide, observational study aiming to recruit non-valvular and valvular AF patients in Indonesia. The registry was started in January 2020 with a planned 2 years of recruitment. There are 2 respondents for this registry: non-cohort and cohort respondents. Non-cohort registry respondents are AF patients at hospitals who fulfill inclusion and exclusion criteria but did not consent for a 24 month follow up. Whereas patients who consented for a 24 month follow up were included as cohort registry respondents. Key data collected includes basic sociodemographic information, symptoms and signs, medical history, results of physical examination and laboratory test, details of diagnostics and treatment measures and events. Results: Currently, a total of 1568 respondents have been enrolled in the non-cohort registry, including 1065 respondents with non-valvular AF (67.8%) and 503 respondents with valvular AF (32.2%). We believe that the OneAF registry will provide insight into the regional variability of anticoagulant treatment for AF, the implementation of rhythm/rate control approaches, and the clinical outcomes concerning cardiocerebrovascular events. Trial registration: Registered at clinicaltrials.gov (NCT04222868).

Validity of MENARI plus (self‐pulse assessment and clinical scoring) mobile apps for detecting atrial fibrillation in high‐risk population

“…Anat et al 14 reported that AF detection reached 6% at age ≥50 years with CHA₂DS₂‐VASc values >1. This study was also conducted on patients aged 50–75 years because according to OneAF registry data, it is said that the average age of AF patients in Indonesia is 57.52 (50.6 ± 78.2) years 15 …”

Statement from the Asia Summit: Current state of arrhythmia care in Asia

“…However, data from a national registry showed that in Indonesia patients are younger, with the majority between 41 and 60 years old (Figure 4), and permanent AF is common (31%) (Figure 5). 19 AF distribution varies depending on ethnicity. Based on risk factors, the reported prevalence of AF is lower than expected, suggesting the possibility of underidentification.…”

“…When anticoagulation is prescribed, warfarin is used because direct oral anticoagulants are not covered by national health insurance. However, the time in therapeutic range with warfarin treatment is only 37% 19,20 . The availability of test facilities that can measure the international normalized ratio (INR) is limited and not well distributed in Indonesia, which has led to the reluctance of primary care physicians to prescribe warfarin.…”

“…Permanent: persistent AF with no future attempt for rhythm control. Persistent: AF duration >1 week 19 …”

Statement from the Asia Summit: Current state of arrhythmia care in Asia

“…However, the time in therapeutic range with warfarin treatment is only 37%. 19 , 20 The availability of test facilities that can measure the international normalized ratio (INR) is limited and not well distributed in Indonesia, which has led to the reluctance of primary care physicians to prescribe warfarin. The prevalence of hypertension in all provinces ranges from 22% to 39.6% Figure 6 .…”